Atrium Therapeutics, Inc.
NASDAQ:RNABiotechnology
+$0.16 today
- Market cap
- $143.23M
- Beta
- 0.42
- P/E (TTM)
- -3.3
- EPS (TTM)
- -$3.78
Volume 0.22M
Average 0.35M
RNA Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
Atrium Therapeutics, Inc.NASDAQ: RNA
Other Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other current liabilities of $6.98M in Q1 FY2026
Q1 FY2026 other current liabilities was $6.98M.
Context
- Other current liabilities amounted to 2.4% of total assets at the end of Q1 FY2026.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 3.15M USD
- Year-over-year change
- —
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.15M | — |
Other Current Liabilities vs competitors
How RNA compares with its peers on the latest reported figures
No competitor Other Current Liabilities figures are available to compare.
Balance Sheet
Atrium Therapeutics, Inc.
NASDAQ:RNA
Intrinsic Alpha fair value
Locked
Current Price
$6.64
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.